+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 34 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating treatments for advanced HRD-positive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma, and clear cell carcinoma of the ovary in patients who have no residual tumor after primary tumor debulking. This phase II, multicenter, randomized, open-label study compares the recurrence-free survival of patients receiving either 3 cycles of carboplatin plus paclitaxel followed by maintenance therapy with niraparib or 6 cycles of the same chemotherapy plus niraparib maintenance. The study includes patients with specific disease stages FIGO IIIA to IV and uses genetic testing to stratify patients based on tumor characteristics.

Age: 18Years +FEMALEPhase 2
50 locations
P

Actively Recruiting

Researchers are conducting a prospective, multicenter observational study to create a registry for patients diagnosed with unresectable locally advanced or metastatic breast cancer, either after recurrence or as a first diagnosis since January 2016. This study aims to understand the distribution of different breast cancer subtypes and patient characteristics over an 8-year period. No specific treatment is assigned by the study, and clinical decisions are made independently by the treating physicians. Participants are grouped based on breast cancer subtypes characterized by receptors such as Estrogen receptor ER, Progesterone receptor PgR, HER2, and Ki-67 expression levels. The study does not intervene in treatment instead, it observes patients receiving standard care as decided by their doctors. Patients may include males and females, and there is no age upper limit. Data collection includes patient and tumor characteristics, biomarker presence in tumor and blood samples, and the impact of surgery timing on patients initially diagnosed with metastatic disease. During the study, participants medical records and disease management data are accessed for analysis. Researchers collect information over 8 years, including subtype distribution, heredofamilial risk, gender differences in disease progression, and biomarker frequency. Patients can withdraw consent at any time, and the treating clinician is encouraged to follow patients until death or study completion. The studys primary outcome is the number of patients with various breast cancer subtypes, with several secondary outcomes related to disease characteristics and treatment timing.

Age: 18Years +All Genders
40 locations
C

Actively Recruiting

Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.

Age: 18Years +All GendersPhase 3
303 locations
C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
E

Actively Recruiting

Researchers are evaluating new combination treatments for people with locally advanced or metastatic non-small cell lung cancer NSCLC in this Phase II, multi-center, open-label study. The study includes several sub-studies focused on different groups based on tumor genetics and PD-L1 levels, aiming to assess the safety, tolerability, and early anti-tumor effects of these novel regimens. This global study is conducted at approximately 80 centers across 10 countries. Participants receive different combinations of investigational drugs given by intravenous infusion, including rilvegostomig, ramucirumab, and Dato-DXd, depending on their assigned sub-study. Treatments continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. Each sub-study may have a safety run-in phase followed by a dose expansion phase to further evaluate the treatments. Throughout the study, participants undergo regular assessments to monitor tumor response, side effects, and drug levels in the blood. Researchers will track adverse events and measure outcomes like objective response rate, progression-free survival, and overall survival over an average of three years. The study also evaluates pharmacokinetics and immune response to the treatments to better understand how they work and their safety profile.

Age: 18Years +All GendersPhase 2
83 locations
E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and how the body processes a drug called YL201 when combined with atezolizumab in patients with advanced solid tumors, including extensive-stage small cell lung cancer ES-SCLC. This phase IbII, open-label study involves two parts focusing on dose levels and optimization to understand the best way to use YL201 alongside atezolizumab. The study aims to find doses that patients can tolerate and that show potential benefits. Participants receive YL201 through an intravenous infusion on the first day of each 21-day cycle, at doses of 1.2 mgkg, 1.6 mgkg, or 2.0 mgkg, combined with a fixed 1200 mg dose of atezolizumab given the same way and schedule. The study starts with a dose escalation phase, then moves to dose optimization with random assignment to one of the three dosing groups. Depending on results, the study continues with dose expansion using one or two selected dose levels. Treatment continues until the cancer progresses, unacceptable side effects occur, or the participant chooses to stop. During the study, participants undergo evaluations of side effects and dose-limiting toxicities over 21 days, with ongoing monitoring of adverse events until disease progression or death, lasting up to about six years. Secondary outcomes include response rates, duration of response, progression-free and overall survival, and detailed drug pharmacokinetics for up to three years. The long participation allows researchers to gather extensive safety and effectiveness data while closely monitoring participants throughout their treatment journey.

Age: 18Years +All GendersPhase 1Phase 2
38 locations
C

Actively Recruiting

Researchers are studying post-menopausal women who have been treated for hormone receptor-positive early breast cancer. The study compares the amount of the drug letrozole in the bloodstream after multiple doses of a quarterly injectable form called Letrozole SIE to that after multiple doses of the standard daily oral tablet, Femara4. The goal is to evaluate how the two forms of letrozole compare in steady-state bioavailability, and to understand the elimination phase of Letrozole SIE after repeated doses. The study has four parts a Screening period, Treatment Period 1 TP1, Treatment Period 2 TP2, and an Extension Period. After screening, participants are randomly assigned to receive either US-sourced or EU-sourced oral Femara4 daily for 14 days in TP1 to reach steady-state drug levels. Then, in TP2, all participants receive quarterly injections of Letrozole SIE to achieve steady-state. A subset of about 60 participants will continue into the Extension Period to further assess drug elimination after multiple doses. Participants will undergo breast imaging before baseline and regular assessments including drug concentration measurements, bone mineral density scans, and monitoring for adverse events and injection site reactions. The primary measure is the area under the concentration-time curve at steady state. Safety and other pharmacokinetic parameters will be tracked from consent through the follow-up visits, which may last up to 421 days for some participants. The total study duration includes screening, treatment, and possible extension periods.

Age: 18Years - 80YearsFEMALEPhase 1
21 locations
O

Actively Recruiting

Researchers are evaluating patient satisfaction, effectiveness, and safety of the drug Atezolizumab given by subcutaneous injection in people treated for certain cancers in routine healthcare settings. This observational study includes participants with specific types of lung cancer and hepatocellular carcinoma who receive Atezolizumab according to approved indications without altering their usual treatment plans. Participants are grouped into cohorts based on their diagnosis, including early-stage non-small cell lung cancer NSCLC after surgery and chemotherapy, metastatic NSCLC, extensive-stage small cell lung cancer ES-SCLC, and advanced or unresectable hepatocellular carcinoma HCC. The treatment with Atezolizumab is administered by the participants doctor independently of study participation. Throughout the study, participants report their satisfaction with the subcutaneous therapy using questionnaires at specific treatment cycles, and their quality of life is assessed by standardized tools. Researchers monitor survival outcomes and adverse events for up to approximately 3.5 years. The study captures real-world data on treatment experiences and monitors safety and effectiveness during routine clinical care.

Age: 18Years +All Genders
92 locations
E

Actively Recruiting

Researchers are evaluating how well intranasal esketamine works alongside standard care to quickly reduce symptoms of major depressive disorder MDD in adolescents with acute suicidal thoughts or behaviors. The study compares esketamine plus comprehensive standard care to a psychoactive placebo plus standard care to understand its effectiveness and safety in this population. Participants will be randomly assigned to one of two groups receiving treatment twice weekly for 4 weeks. One group receives intranasal esketamine starting at 84 mg, possibly reduced to 56 mg based on investigator judgment, along with oral placebo. The other group receives oral midazolam and intranasal placebo following a similar dosing schedule. The study allows dose flexibility between 56 mg and 84 mg for esketamine during treatment. During the study, participants will be monitored through various assessments including depression rating scales and measures of suicidality at baseline, 24 hours after the first dose, and throughout the 25-day treatment period. Researchers will evaluate changes in depressive symptoms, suicidality severity, and quality of life. Safety and adherence will be carefully observed, with the study continuing until primary outcome evaluation and completion by 2031.

Age: 12Years - 17YearsAll GendersPhase 3
49 locations
P

Actively Recruiting

Researchers are conducting a Phase III international trial to study the effects and safety of androgen deprivation therapy ADT with or without darolutamide in men newly diagnosed with metastatic prostate cancer who have vulnerable functional abilities. This study specifically includes patients who have not chosen treatment with docetaxel or other androgen receptor pathway inhibitors. The goal is to evaluate how these treatments impact disease progression and patient health over time. Participants will be randomly assigned to one of two groups one receiving ADT plus darolutamide 600 mg taken orally twice daily, and the other receiving ADT plus a placebo taken with the same schedule. Treatment will continue until imaging shows disease progression or until the patient or doctor decides to stop for reasons such as side effects or other health issues. After stopping treatment, patients will enter a follow-up phase lasting up to 10 years to monitor survival, further treatments, and any ongoing or new side effects. During the study, participants will undergo regular assessments including imaging scans to check for cancer progression, blood tests, evaluations of urinary symptoms, and quality of life questionnaires. Researchers will track outcomes like progression-free survival, overall survival, symptom changes, and adverse events. Monitoring visits will occur periodically both during treatment and follow-up to gather comprehensive data on health status and treatment effects.

Age: 18Years +MALEPhase 3
95 locations

1-10 of 34

1